8-K: Anteris Secures $320M Capital, Medtronic Strategic Investment

Anteris Technologies Global Corp. announced a $90 million strategic investment from Medtronic plc and a combined $320 million capital raise to advance its DurAVR THV and PARADIGM trial.

Summary

• Anteris Technologies Global Corp. completed a $90 million strategic investment from Medtronic plc.
• This investment, combined with an underwritten public offering of common stock, resulted in $320 million in gross proceeds.
• The capital will fund the global pivotal PARADIGM trial and support the global commercialization of the DurAVR Transcatheter Heart Valve (THV).
• The PARADIGM Trial is a prospective randomized controlled trial comparing DurAVR THV to commercially available TAVRs, enrolling approximately 1000 patients.
• First patients for the PARADIGM Trial were enrolled and implanted during the fourth quarter of 2025.
• The DurAVR THV is a balloon-expandable, biomimetic valve made with ADAPT tissue, which is FDA-cleared and has been used in over 55,000 patients worldwide.

Sentiment

Score: 9

Explanation: The announcement of a significant strategic investment from a major industry player like Medtronic, coupled with a substantial capital raise, provides strong validation and financial backing for Anteris' core product and clinical trials. This is a highly positive development for the company's future prospects and market position.

Positives

• Secured a significant $90 million strategic investment from Medtronic plc, a major medical technology company.
• Successfully raised a total of $320 million in gross proceeds, providing substantial capital for development and commercialization.
• The investment provides strong validation of the DurAVR THV program from both capital markets and a strategic innovator.
• Collaboration with Medtronic may expand into other strategic areas in the future.
• The DurAVR THV is a clinically important, evidence-supported product designed to improve patient lives.
• The ADAPT tissue technology used in DurAVR THV is FDA-cleared and has a decade of clinical use in over 55,000 patients.

Risks

• Forward-looking statements are subject to risks, uncertainties, and assumptions, including those described under Risk Factors in Anteris' Annual Report on Form 10-K for the fiscal period ended December 31, 2024, and Quarterly Report on Form 10-Q for the period ended September 30, 2025.
• The success of the PARADIGM Trial and regulatory approval of DurAVR THV are subject to inherent clinical trial risks.

Future Outlook

The company plans to use the raised capital to continue executing the global pivotal PARADIGM trial and advance towards global commercialization of the DurAVR Transcatheter Heart Valve. There is potential for the collaboration with Medtronic to expand into other strategic areas in the future. The PARADIGM trial aims to assess the non-inferiority of DurAVR THV against commercially available TAVRs on key patient outcomes at one year post-procedure.

Management Comments

• "This strategic investment, along with our underwritten offering of common stock, represent an important milestone for our company. It also provides strong validation of our program from the capital markets and a major strategic innovator." Wayne Paterson, Anteris Vice Chairman and CEO.
• "The investment aligns two organizations in their commitment to advancing valve science in a way that is disciplined and focused on longterm patient benefit." John Seaberg, Chairman of the Anteris Board.
• "Our investment in differentiated innovation like the DurAVR THV technology – which has the potential to offer improved valve performance in a balloon-expandable platform – is core to our commitment to define and drive the future of TAVR, meeting the needs of more aortic stenosis patients and heart teams with a comprehensive portfolio." Jorie Soskin, Vice President and General Manager of the Structural Heart business in Medtronic's Cardiovascular portfolio.

Industry Context

This announcement signifies a major validation for Anteris within the highly competitive Transcatheter Aortic Valve Replacement (TAVR) market. Medtronic, a pioneer and leader in TAVR innovation, investing in Anteris' DurAVR THV technology suggests a potential shift or enhancement in the TAVR landscape, particularly towards biomimetic valves and improved valve performance. The collaboration could accelerate Anteris' market penetration and potentially influence future TAVR design and clinical standards.

Comparison to Industry Standards

• Medtronic, a pioneer in TAVR innovation, has invested in Anteris, indicating a strong belief in DurAVR THV's potential to offer improved valve performance in a balloon-expandable platform, which is a key differentiator in the TAVR market.
• The PARADIGM Trial is a prospective randomized controlled trial (RCT) designed for head-to-head comparison against commercially available TAVRs, a rigorous standard for demonstrating non-inferiority or superiority in the medical device industry.
• The DurAVR THV's use of ADAPT tissue, which is FDA-cleared and has been clinically used for over 10 years in over 55,000 patients, provides a strong foundation of proven material technology, comparable to established tissue technologies in other heart valve products.

Stakeholder Impact

• Shareholders: Significant positive impact due to strong validation from Medtronic, substantial capital infusion, and potential for accelerated product development and commercialization, likely leading to increased share price.
• Employees: Positive impact through increased job security, potential for growth, and resources to advance innovative medical technology.
• Customers (Hospitals/Clinicians): Potential for a new, differentiated TAVR option (DurAVR THV) with improved valve performance, backed by a major industry player.
• Patients: Potential for improved treatment outcomes for aortic stenosis patients with the DurAVR THV.
• Creditors: Improved financial stability and reduced risk due to significant capital raise.

Next Steps

• Continue execution of the global pivotal PARADIGM Trial.
• Advance towards global commercialization of the DurAVR Transcatheter Heart Valve (THV).
• Potential expansion of collaboration with Medtronic into other strategic areas.
• Ongoing recruitment and implantation of patients in the PARADIGM Trial, with planned expansion across other geographies.

Key Dates

Recommendation

The strategic investment from Medtronic, a global leader in medical technology, provides significant validation for Anteris' DurAVR THV and its PARADIGM trial. The combined $320 million capital raise substantially de-risks the company's financial position, enabling it to fully fund its pivotal trial and advance towards global commercialization. This partnership and funding are transformative, positioning Anteris for accelerated growth and market penetration in the high-value TAVR segment, making it a compelling "strong buy" for long-term investors.

Keywords

Anteris Technologies, Medtronic, Strategic Investment, TAVR, Transcatheter Aortic Valve Replacement, DurAVR THV, PARADIGM Trial, Aortic Stenosis, Medical Devices, Structural Heart, ADAPT tissue, Capital Raise, Biomimetic Valve, Clinical Trial, NASDAQ: AVR, ASX: AVR, NASDAQ: MDT